Cubist Pharmaceuticals Inc., the Lexington drug company best known for the antibiotic Cubicin, said it has obtained the rights to ceftolozane in certain Asia-Pacific and Middle East territories from Astellas Pharma Inc.
With the attainment of these rights, Cubist said it now owns worldwide rights to develop, manufacture, and commercialize ceftolozane/tazobactam. Ceftolozane is a drug candidate with the potential to treat for urinary tract and intraabdominal infections. It is currently in trials.
Cubist previously obtained the rights, outside of the Asia-Pacific and Middle East territories covered by today’s agreement with Astellas, to develop and commercialize ceftolozane/tazobactam through its acquisition of Calixa Therapeutics Inc. in 2009.
Under the terms of the agreement disclosed Monday, Astellas will receive an upfront payment of $25 million, and sales of ceftolozane/tazobactam made in the newly-obtained territories will be counted towards the existing commercial milestone and royalty terms of the original agreement. Cubist said it will fund the upfront payment with cash on hand.